Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00003864
DRKS00003864
Completed
Not Applicable

Stereotactic ablative radiotherapy (SABR) for small lung tumors: retrospective analysis 2009-2010 - SABR

niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde0 sites39 target enrollmentFebruary 18, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC34C78.0Malignant neoplasm of bronchus and lungSecondary malignant neoplasm of lung

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C34
Sponsor
niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde
Enrollment
39
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 18, 2016
End Date
December 31, 2011
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Freiburg, Klinik für Strahlenheilkunde

Eligibility Criteria

Inclusion Criteria

  • •presence of one or two FDG\-PET positive pulmonary nodules \- Karnofsky index \>/\= 60%
  • •\- Life expectancy \> 6 months
  • •\- Age \> 18 years (no other age limits)
  • •\- Informed consent signed in accordance with institutional protocol

Exclusion Criteria

  • •\- NSCLC: FDG\-PET N\+ if not ruled out by mediastinoscopy or other tissue sampling
  • •\- in metastases: disseminated progressive disease without local control to be reasonably expected by current treatment
  • •\- Histologically proven SCLC
  • •\- More than two lesions to treat
  • •\- Diameter of tumor \> 5cm
  • •\- Systemic therapy \+/\- one week of treatment
  • •\- psychological/mental status does not allow informed consent and participation in QoL assessments
  • •\- Pregnancy

Outcomes

Primary Outcomes

Not specified

Similar Trials

Withdrawn
Phase 2
Stereotactic ablative radiotherapy (SABR) after systemic antineoplastic treatment for patients with unresectable oligometastases (lung; liver; adrenal glands) from solid tumours: SARASTRO Trial (Stereotactic Ablative Radiotherapy After Systemic TReatment for Oligometastases) A randomised phase II trialmetastasesspread out cancer10027476
NL-OMON37714niversitair Medisch Centrum Groningen80
Completed
Phase 2
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): A Randomized Phase II Trialcancer spread to other parts of the bodymetastatic cancer10027476
NL-OMON37922Vrije Universiteit Medisch Centrum20
Active, not recruiting
Phase 2
High dose Radiation therapy to eradicate early metastatic prostate cancer as an alternative to hormone or chemotherapy: a prospective phase II study
ACTRN12618000566235Integrated Clinical Oncology Network Pty Ltd (ICON)208
Active, not recruiting
Phase 2
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)Metastatic Tumors
NCT01446744Lawson Health Research Institute99
Withdrawn
Phase 2
ungTech Stereotactic Body Radiotherapy (SBRT) of inoperable centrally located NSCLC: A phase II study in preparation for a randomized phase III trialLung CancerNon-small-cell lung cancer10038666
NL-OMON40781European Organisation for Research in Treatment of Cancer (EORTC)42